Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

15.3K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
15.3K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

7.3K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CA19.9 Response and Tumor Size Predict Recurrence Following Post-neoadjuvant Pancreatectomy in Initially Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma.

Annals of surgical oncology·2022
Same author

Metastatic grade 1 meningioma lacking genetic abnormalities commonly associated with bad prognosis.

Pathology, research and practice·2022
Same author

The tumour immune microenvironment and microbiome of pancreatic intraductal papillary mucinous neoplasms.

The lancet. Gastroenterology & hepatology·2022
Same author

Integrative characterization of intraductal tubulopapillary neoplasm (ITPN) of the pancreas and associated invasive adenocarcinoma.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2022
Same author

Loss of FGFR4 promotes the malignant phenotype of PDAC.

Oncogene·2022
Same author

pRB immunostaining in the differential diagnosis between pleomorphic xanthoastrocytoma and glioblastoma with giant cells.

Histopathology·2022

Related Experiment Video

Updated: Mar 12, 2026

Bioluminescent Orthotopic Model of Pancreatic Cancer Progression
09:25

Bioluminescent Orthotopic Model of Pancreatic Cancer Progression

Published on: June 28, 2013

27.6K

Hypermutation In Pancreatic Cancer.

Jeremy L Humphris1, Ann-Marie Patch2, Katia Nones2

  • 1The Kinghorn Cancer Centre, Darlinghurst, and the Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, Sydney, New South Wales, Australia.

Gastroenterology
|November 19, 2016
PubMed
Summary
This summary is machine-generated.

Pancreatic cancer, often lacking effective treatments, shows potential for immunotherapy. Researchers analyzed 385 genomes, identifying DNA repair defects linked to higher mutation loads, suggesting new patient selection strategies for immune checkpoint inhibitors.

Keywords:
Cancer GeneticsPancreatic AdenocarcinomaSequencingSomatic Rearrangement

More Related Videos

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.5K
Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

12.3K

Related Experiment Videos

Last Updated: Mar 12, 2026

Bioluminescent Orthotopic Model of Pancreatic Cancer Progression
09:25

Bioluminescent Orthotopic Model of Pancreatic Cancer Progression

Published on: June 28, 2013

27.6K
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.5K
Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

12.3K

Area of Science:

  • Oncology
  • Genomics
  • Cancer Research

Background:

  • Pancreatic cancer exhibits significant molecular diversity, limiting therapeutic options.
  • Immune checkpoint inhibitor efficacy in other cancers correlates with increased mutation burden and DNA repair defects.

Purpose of the Study:

  • To define hypermutation and its underlying causes in pancreatic cancer.
  • To investigate the role of DNA repair defects in pancreatic cancer mutational profiles.

Main Methods:

  • Interrogation of 385 pancreatic cancer genomes.
  • Analysis of mutational signatures to infer DNA repair defects.
  • Identification of mismatch repair deficiency mechanisms.

Main Results:

  • Mutational signatures indicating DNA repair defects were prevalent in hypermutated pancreatic tumors.
  • Mismatch repair deficiency, through MLH1 and MSH2 inactivation, was found in 1% of tumors.
  • Mutation load varies significantly across individual pancreatic cancers.

Conclusions:

  • Defining pancreatic cancer mutation load and selecting appropriate assays are crucial for immunotherapy clinical trial design.
  • Identifying specific DNA repair defects may guide patient selection for novel pancreatic cancer therapies.